.Attribute Medicine, Published online: thirteen September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized stage 3b/4 DESTINY-Breast12 research study, trastuzumab deruxtecan (T-DXd) treatment of patients with HER2+ advanced breast cancer cells as well as active or dependable human brain metastases revealed constant intracranial task and also wide spread efficacy of T-DXd.